Computer analysis points to a new target on glioblastoma cells
Original title: Machine learning-driven identification of DLL3 as a molecular target and development of a DLL3-binding cyclic peptide for glioblastoma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done on computers and on cells in a dish, not in people.
The short version
Scientists found a protein that sits on glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary cells, and they built a small molecule that sticks to it in lab tests.
What was studied. Researchers used computer programs to compare gene activity in glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary tumors and in normal brain tissue, using data from public databases. They then designed a small ring shaped molecule called a cyclic peptide and tested it on cells in the lab.
What they found. The computer analysis picked a protein called DLL3 as a top target. DLL3 was high in glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary and low in normal brain tissue. A peptide called IMP-3 was predicted to attach to DLL3 and stayed attached during computer simulations. A glowing version of it, MPA-IMP-3, built up in glioblastoma cells and glowed more strongly there than in normal brain cells.
What this means, and what it doesn't
What it could mean: This gives researchers a possible handle to grab onto glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary cells. The team's goal is to use a target like this to carry treatment straight to tumor cells and spare normal brain. That work has not been done yet.
What it doesn't mean: This does not mean a new treatment exists. The work was done on computers and on cells in a dish. No person has been given this peptide. It is very early stage research, and it is far from anything a doctor can offer at a clinic. It is not a cure and it is not a promise of one. Many ideas that look good in the lab never work in people.
Source: PubMed, July 14, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.